Q3 2023 13F Holders as of 30 Sep 2023
-
Type / Class
-
Debt / NOTE 3.500% 9/1
-
Unit price / market price
-
$1.26
-
Total 13F principal
-
$93,849,454
-
Principal change
-
-$11,723,342
-
Total reported value
-
$118,114,618
-
Number of holders
-
12
-
Value change
-
-$56,841,055
-
Number of buys
-
4
-
Number of sells
-
9
Institutional Holders of APELLIS PHARMACEUTICALS INC - NOTE 3.500% 9/1 as of Q3 2023
As of 30 Sep 2023 APELLIS PHARMACEUTICALS INC - NOTE 3.500% 9/1 had 12 institutional bondholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions held a total of $93,849,454 principal (par value or face value) of the bond of the company.
Largest 10 bondholders included DeepCurrents Investment Group LLC, Linden Advisors LP, LAZARD ASSET MANAGEMENT LLC, WOLVERINE ASSET MANAGEMENT LLC, Voya Investment Management LLC, D. E. Shaw & Co., Inc., WELLINGTON MANAGEMENT GROUP LLP, JPMORGAN CHASE & CO, PALISADE CAPITAL MANAGEMENT, LP, and CITIGROUP INC.
This table shows 12 bond principal holders of the security as of 30 Sep 2023.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Principal |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.